Eiger BioPharmaceuticals closes merger with Celladon

Published: 23-Mar-2016
Finance Pharmaceutical

The US firm is developing a clinical stage pipeline of orphan disease programmes


Eiger BioPharmaceuticals, a privately owned Californian biopharmaceutical firm, has completed its merger with Celladon. In connection with the merger, Celladon has changed its name to Eiger BioPharmaceuticals. The firm, also based in California, is focused on developing molecular therapies for congestive heart failure through the application of scientific discoveries in molecular cardiology.

Prior to the merger, Eiger received gross proceeds of US$39.5m in new investment from a combination of current and new investors including HBM Healthcare Investments, Vivo Capital, InterWest Partners, RA Capital Management, Sabby Management, Sphera Global Healthcare, Perceptive Advisors and Monashee Capital Partners.

Together with approximately $26.1m in pre-merger cash on Celladon's balance sheet, the combined company has approximately $59m in cash.

'We are very pleased to complete this merger, which marks a significant milestone for Eiger. We are transitioning from a private company to a publicly-traded company through this merger, and significantly increasing our financial resources,' said David Cory, President and CEO of Eiger.

He said the funds would support operations and enable the firm to advance its four orphan disease programmes for treating hepatitis delta, hypoglycaemia, pulmonary arterial hypertension and lymphoedema.

  • Companies:
  • Eiger BioPharmaceuticals
See more

You may also like

Pharmaceutical

Eiger Bio strengthens senior management team

Read more
By hiring Debra Odink as Senior Vice President of Technical Operations

Trending Articles

  1. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  2. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  3. How pharma packaging manufacturers role is evolving: the case of extractables testing As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
  4. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  5. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Pharmaceutical

Eiger Bio strengthens senior management team

By hiring Debra Odink as Senior Vice President of Technical Operations
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Can creative carriers deliver the goods?

There are many reasons why conventional drug delivery technologies may not be effective and a more creative approach is required to convey the active ingredient to its destination. Dr Sarah Houlton looks at the more promising technologies in development
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now